◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

HomeAll stocks › UPC

Universe Pharmaceuticals INC (UPC) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Drug Manufacturers - Specialty & Generic · DATA UPDATED 2026-07-09

Universe Pharmaceuticals INC (UPC) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Ji'An, China with about 216 employees. Its market capitalization is roughly $4 million. In the fiscal year ended 2025-09-30, UPC reported $18M in revenue and ($4M) in net income.

Universe Pharmaceuticals INC, through its subsidiaries, engages in the manufacturing, marketing, distribution, and sales of traditional Chinese medicine derivative products in China.

Interactive charts & full statements → Open the UPC valuation workbench →

UPC Revenue & Earnings History — Annual Income Statement

Income statement2025-09-302024-09-302023-09-302022-09-302021-09-30
Total Revenue$18M$23M$32M$40M
Gross Profit$6M$6M$10M$22M
Operating Income (EBIT)($3M)($8M)($4M)($7M)
Net Income($4M)($9M)($7M)($8M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

UPC Free Cash Flow History

Cash flow2025-09-302024-09-302023-09-302022-09-302021-09-30
Dividends Paid$0M$0M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

UPC Balance Sheet History

Balance sheet2025-09-302024-09-302023-09-302022-09-302021-09-30
Total Assets$69M$68M$42M$60M
Total Liabilities$13M$22M$14M$13M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive UPC viewer.

Other Companies in Drug Manufacturers - Specialty & Generic

← UPBDAll stocksUPLD →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.